In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...